1Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves' orbitopathy(GO) on management of GO[J]. European Journal of Endocrinology, 2008, 158: 273-285.
2Wiersinga WM. Autoimmunity in Graves' ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors?[J]. J Clin Endocrinol Metab, 2011, 96: 2386-2394.
3Gillespie E, Papageorgiou KI, Femando R, et al. Increased expression of TSH receptor by fibroeytes in thyroid-associated ophthalmopathy leads to chemokine production[J]. The Journal of Clinical Endocrinology & Metabolism, 2012, 97(5): E740-746.
4van Zeijl C J, Fliers E, van Koppen CJ, et al. Thyrotropin receptor- stimulating Graves' disease immunoglobulins induce hyaluronan synthesis by differentiated orbital fibroblasts from patients with Graves' ophthalmopathy not only via cyclic adenosine monophosphate signaling pathways[J].Tbyroid, 2011, 21: 169-176.
5Kumar S, Nadeem S, Sun MN, et al. A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves' ophthalmopathy[J]. J Mol Endocrinol, 2011,46: 155-163.
6Smith TJ, Hegedus L, Douglas RS. Role of insulin-like growth factor- I(IGF-1) pathway in the pathogenesis of Graves' orbitopathy[J]. Best Pract Res Clin Endocrinol Metab, 2012, 26(3): 291-302.
7Pritchard J, Horst N, Cruikshank W, et al. Igs from patients with Graves disease induce the expression of T cell chemoattractants in their fibroblasts[J]. J lmmunol, 2002, 168: 942-950.
8Gillespie EF, Nupur Raychaudhuri N, Papageorgiou KI, et al. lnterleukin-6 Production in CD40-Engaged Fibrocytes in Thyroid-Associated Ophthalmopathy: Involvement of Akt and NF-κB[J]. Invest Ophthalmol Vis Sci, 2012, 53(12): 7746-7753.
9Stan MN, Garrity JA, Bahn RS, et al. The evaluation and treatment of graves ophthalmopathy[J]. Med Clin North Am, 2012, 96(2): 311-328.
10Grubeck-Loebenstein B, Trieb K, Sztankay A, et al. Retrobulbar T cells from patients with Graves' ophthalmopathy are CD8+ and specifically recognize autologous fibroblasts[J]. J Clin Invest, 1994, 93: 2738-2743.
5Fazio S,Palmieri E A,Lombardi G,et al.Effects of thyroid hormone on the cardiovascular system[J].Recent Progress in Hormone Research,2004,59(1):31-50.
6Andrade VA,Gross JL,Maia AL.The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves'hyperthyroidism:one-year follow-up of a prospective,randomized study[J].The Journal of Clinical Endocrinology&Metabolism,2001,86(8):3488-3493.
7Miyauchi S,Matsuura B,Onji M.Increased Levels of Serum lnterleukin-18 in Graves'Disease[J].Thyroid,2000,10(9):815-819.
8Aniszewski JP,Valyasevi RW,Bahn RS.Relationship between disease duration and predominant orbital T cell subset in Graves'ophthalmopathy[J].The Journal of Clinical Endocrinology&Metabolism,2000,85(2):776-780.
9Okumura M,Hidakay OH,Matsuzuka F,et al.CD30expression and interleukin-4 and interferon-y production of intrathyroidal lymphocytes in Graves'disease[J].Thyroid,1999,9(4):333-339.
10Bschor T,Baethge C,Adli M,et al.Hypothalamic-pituitarythyroid system activity during lithium augmentation therapy in patients with unipolar major depression[J].Journal of Psychiatry and Neuroscience,2003,28(3):210.
